吗啡治疗特发性肺纤维化咳嗽(PACIFY COUGH):一项前瞻性、多中心、随机、双盲、安慰剂对照、双向交叉试验
PACIFY COUGH是一项2期、多中心、随机、双盲、安慰剂对照、双向交叉试验,在英国三个专科中心纳入44例特发性肺纤维化伴咳嗽(VAS≥30 mm、咳嗽>8周)患者。患者按1:1随机接受缓释吗啡5 mg口服每日两次或安慰剂治疗14天,经7天洗脱后交叉。主要终点为第14天客观清醒咳嗽频率较基线的百分比变化。意向性治疗分析显示,吗啡较安慰剂降低客观清醒咳嗽频率39.4%(95%CI -54.4至-19.4;p=0.0005);吗啡组平均日间咳嗽频率从基线21.6次/小时降至12.8次/小时,安慰剂组无变化(21.5次/小时至20.6次/小时)。吗啡组不良事件17/43(40%),安慰剂组6/42(14%),主要为恶心和便秘。
要点
- 在特发性肺纤维化伴咳嗽(VAS≥30 mm、咳嗽>8周)患者中,缓释吗啡5 mg口服每日两次、共14天,较安慰剂降低客观清醒咳嗽频率39.4%(95%CI -54.4至-19.4;p=0.0005)。
- 吗啡组平均日间咳嗽频率从基线21.6次/小时(SE 1.2)降至12.8次/小时(SE 1.2),安慰剂组从21.5次/小时(SE 1.2)至20.6次/小时(SE 1.2),无变化。
- 吗啡组不良事件17/43(40%),安慰剂组6/42(14%);主要副作用为恶心6/43(14%)和便秘9/43(21%)。
- 安慰剂组发生1例严重不良事件(死亡);两组治疗依从性均为98%。
- 作者认为,低剂量缓释吗啡显示出作为特发性肺纤维化患者咳嗽姑息治疗有效药物的前景,未来研究应关注更长期的研究。
适用人群与场景
- 年龄40-90岁、诊断为特发性肺纤维化5年以内、自报咳嗽持续>8周且咳嗽视觉模拟量表(VAS)评分≥30 mm的患者。
- 研究在英国三个专科中心进行,纳入因特发性肺纤维化相关咳嗽就诊的患者。
诊断标准与关键阈值
- 咳嗽视觉模拟量表(VAS)评分≥30 mm。
- 自报咳嗽持续>8周。
- 特发性肺纤维化诊断在5年以内。
处置流程与药物剂量
- 缓释吗啡5 mg口服每日两次,治疗14天。
- 安慰剂口服每日两次,治疗14天。
- 两种治疗之间设7天洗脱期。
研究设计与关键结果
- 研究类型:2期、多中心、随机、双盲、安慰剂对照、双向交叉试验;在英国三个专科中心进行;纳入44例患者,平均年龄71岁(SD 7.4),男性31/44(70%)、女性13/44(30%)。
- 肺功能:平均用力肺活量(FVC)2.7 L(SD 0.76),平均预测FVC 82%(17.3),平均预测一氧化碳弥散量48%(10.9)。
- 主要终点:意向性治疗分析中,吗啡较安慰剂降低客观清醒咳嗽频率39.4%(95%CI -54.4至-19.4;p=0.0005)。
- 咳嗽频率变化:吗啡组平均日间咳嗽频率从基线21.6次/小时(SE 1.2)降至12.8次/小时(SE 1.2);安慰剂组从21.5次/小时(SE 1.2)至20.6次/小时(SE 1.2),无变化。
- 完成治疗情况:44例随机患者中,43例完成吗啡治疗,41例完成安慰剂治疗。
- 依从性:吗啡组98%,安慰剂组98%。
- 不良事件:吗啡组17/43(40%),安慰剂组6/42(14%);主要副作用为恶心6/43(14%)和便秘9/43(21%)。
- 严重不良事件:安慰剂组发生1例严重不良事件(死亡)。
证据类型、等级与局限
- 证据类型:2期、多中心、随机、双盲、安慰剂对照、双向交叉试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在特发性肺纤维化相关咳嗽患者中,低剂量缓释吗啡在14天内较安慰剂显著降低客观咳嗽计数。
- 作者认为,吗啡显示出作为特发性肺纤维化患者咳嗽姑息治疗有效药物的前景,未来研究应关注更长期的研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive fibrotic lung disease, with most patients reporting cough. Currently, there are no proven treatments. We examined the use of low dose controlled-release morphine compared with placebo as an antitussive therapy in individuals with idiopathic pulmonary fibrosis.
METHODS: The PACIFY COUGH study is a phase 2, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial done in three specialist centres in the UK. Eligible patients aged 40-90 years had a diagnosis of idiopathic pulmonary fibrosis within 5 years, self-reported cough (lasting >8 weeks), and a cough visual analogue scale (VAS) score of 30 mm or higher. Patients were randomly assigned (1:1) to placebo twice daily or controlled-release morphine 5 mg orally twice daily for 14 days followed by crossover after a 7-day washout period. Patients were randomised sequentially to a sequence group defining the order in which morphine and placebo were to be given, according to a computer-generated schedule. Patients, investigators, study nurses, and pharmacy personnel were masked to treatment allocation. The primary endpoint was percentage change in objective awake cough frequency (coughs per h) from baseline as assessed by objective digital cough monitoring at day 14 of treatment in the intention-to-treat population, which included all randomised participants. Safety data were summarised for all patients who took at least one study drug and did not withdraw consent. This study was registered at ClinicalTrials.gov, NCT04429516, and has been completed.
FINDINGS: Between Dec 17, 2020, and March 21, 2023, 47 participants were assessed for eligibility and 44 were enrolled and randomly allocated to treatment. Mean age was 71 (SD 7·4) years, and 31 (70%) of 44 participants were male and 13 (30%) were female. Lung function was moderately impaired; mean forced vital capacity (FVC) was 2·7 L (SD 0·76), mean predicted FVC was 82% (17·3), and mean predicted diffusion capacity of carbon monoxide was 48% (10·9). Of the 44 patients who were randomised, 43 completed morphine treatment and 41 completed placebo treatment. In the intention-to-treat analysis, morphine reduced objective awake cough frequency by 39·4% (95% CI -54·4 to -19·4; p=0·0005) compared with placebo. Mean daytime cough frequency reduced from 21·6 (SE 1·2) coughs per h at baseline to 12·8 (1·2) coughs per h with morphine, whereas cough rates did not change with placebo (21·5 [SE 1·2] coughs per h to 20·6 [1·2] coughs per h). Overall treatment adherence was 98% in the morphine group and 98% in the placebo group. Adverse events were observed in 17 (40%) of 43 participants in the morphine group and six (14%) of 42 patients in the placebo group. The main side-effects of morphine were nausea (six [14%] of 43 participants) and constipation (nine [21%] of 43). One serious adverse event (death) occurred in the placebo group.
INTERPRETATION: In patients with cough related to idiopathic pulmonary fibrosis, low dose controlled-release morphine significantly reduced objective cough counts over 14 days compared with placebo. Morphine shows promise as an effective treatment to palliate cough in patients with idiopathic pulmonary fibrosis, and longer term studies should be the focus of future research.
FUNDING: The Jon Moulton Charity Trust.
参考来源
- Wu Z, Spencer LG, Banya W, et al. Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial. Lancet Respir Med. 2024. PMID: 38237620. doi:10.1016/S2213-2600(23)00432-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。